<DOC>
	<DOC>NCT00997685</DOC>
	<brief_summary>This is a single arm, open-label phase II study to evaluate the efficacy and safety of Capecitabine plus oxaliplatin (XELOX) in the peri-operative treatment of patients with potentially resectable liver metastasis from colorectal cancer.</brief_summary>
	<brief_title>Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)</brief_title>
	<detailed_description>To investigate the progression free survival (PFS) advantage of Xeloda plus oxaliplatin in the peri-operative treatment of potential resectable metastatic colorectal cancer</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Age of 18 and 65 Histologically confirmed colorectal cancer and two methords of imaging detection confirmed liver metastasis Potentially curable by resection, as determined by a surgeon with hepatic surgery expertise No evidence of extrahepatic disease by chest xray or CT scan of the chest, abdomen, and pelvis Patients with adequate hepative, renal and bone marrow function Signed written informed consent Pregnant or nursing patients (fertile patients must use effective contraception) Other malignancy within the past 5 years except completely resected nonmelanoma skin cancer or carcinoma in situ of the cervix Preexisting grade 2 or greater peripheral neuropathy Concurrent uncontrolled illness Ongoing or active infection Psychiatric illness or social situation that would preclude study compliance Less than 6 months since prior adjuvant fluorouracilbased chemotherapy Prior chemotherapy for liver metastasis Prior oxaliplatin for colorectal cancer Prior or concurrent hepatic artery infusion chemotherapy for metastatic disease Prior or concurrent radiotherapy for metastatic disease Prior or concurrent radiofrequency ablation for metastatic disease concurrent treatment with any other anticancer therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>XELOX</keyword>
	<keyword>potentially resectable liver metastasis from CRC</keyword>
</DOC>